Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
Frequently asked questions
What sector does Generate Biomedicines, Inc. Common Stock (GENB) operate in?
Generate Biomedicines, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Generate Biomedicines, Inc. Common Stock (GENB) current stock price?
As of the latest data, Generate Biomedicines, Inc. Common Stock stock price is $13.11, with a previous close of $12.35. Generate Biomedicines, Inc. Common Stock gained $0.76 in the last trading session, representing a 6.11% increase.
What is Generate Biomedicines, Inc. Common Stock (GENB) current market capitalization?
Generate Biomedicines, Inc. Common Stock market cap is approximately 1.68 billion.
What is Generate Biomedicines, Inc. Common Stock (GENB) Earnings Per Share (EPS)?
The trailing EPS is -$2.44, and the forward EPS is -$2.28.
What is Generate Biomedicines, Inc. Common Stock (GENB) EBITDA?
Generate Biomedicines, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -63.82 million.
Does Generate Biomedicines, Inc. Common Stock (GENB) pay dividends?
No. Generate Biomedicines, Inc. Common Stock does not pay a dividend.
How did Generate Biomedicines, Inc. Common Stock (GENB) perform in its most recent earnings report?
In the last report (June 30, 2026), Generate Biomedicines, Inc. Common Stock posted an EPS surprise of -8.33% and a revenue surprise of 50.21%.
When is Generate Biomedicines, Inc. Common Stock (GENB) next earnings report?
Generate Biomedicines, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Generate Biomedicines, Inc. Common Stock (GENB) beta (volatility) score?
Generate Biomedicines, Inc. Common Stock has a beta of -0.050, indicating lower volatility than the overall market.
